Feldan Therapeutics and Elasmogen Announce Research Agreement with Amgen to Develop Intracellular Biologics Combined Feldan Shuttle and Elasmogen soloMER technology will be used to deliver intracellular candidates for two targets Aberdeen, Scotland and Quebec City, Canada; 9 May 2017: Elasmogen Ltd, focused on the development of next generation biologics, and Feldan Therapeutics, focused on intracellular delivery of proteins, today announce
Feldan Therapeutics will be attending the BIO International Convention 2017 June 19-22, 2017 in San Diego, CA. We are excited to be part in this even again this year! Our team would be happy to meet you there!
QUEBEC CITY, Aug. 22, 2017 – Feldan Therapeutics, Inc. today announced the issuance of its first patent covering the company’s technology, the Feldan Shuttle platform. The United States Patent and Trademark Office (USPTO) granted Feldan Therapeutics the patent on August 22nd, 2017. The Feldan Shuttle platform is a peptide-based delivery method that allows the introduction of foreign
2017 Tous droits réservés | Feldan | Encore une bonne Id !